Log in

NASDAQ:SBPHSpring Bank Pharmaceuticals Stock Price, Forecast & News

-0.01 (-0.60 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $1.65
50-Day Range
MA: $1.39
52-Week Range
Now: $1.65
Volume156,725 shs
Average Volume161,604 shs
Market Capitalization$28.20 million
P/E RatioN/A
Dividend YieldN/A
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. It has a collaboration agreement with Gilead Sciences, Inc. for conducting a Phase II clinical trial examining the co-administration of inarigivir and Vemlidy in patients infected with chronic HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Read More
Spring Bank Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.79 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SBPH



Sales & Book Value

Annual SalesN/A
Book Value$1.65 per share


Net Income$-24,100,000.00


Market Cap$28.20 million
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable

Receive SBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SBPH and its competitors with MarketBeat's FREE daily newsletter.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions

How has Spring Bank Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Spring Bank Pharmaceuticals' stock was trading at $1.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SBPH stock has increased by 42.2% and is now trading at $1.65. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Spring Bank Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Spring Bank Pharmaceuticals.

When is Spring Bank Pharmaceuticals' next earnings date?

Spring Bank Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Spring Bank Pharmaceuticals.

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.29. View Spring Bank Pharmaceuticals' earnings history.

What price target have analysts set for SBPH?

4 Wall Street analysts have issued 1-year target prices for Spring Bank Pharmaceuticals' shares. Their forecasts range from $1.50 to $2.00. On average, they anticipate Spring Bank Pharmaceuticals' stock price to reach $1.73 in the next year. This suggests a possible upside of 5.1% from the stock's current price. View analysts' price targets for Spring Bank Pharmaceuticals.

Has Spring Bank Pharmaceuticals been receiving favorable news coverage?

News coverage about SBPH stock has trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutSpring Bank Pharmaceuticals.

Are investors shorting Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 36,900 shares, a decline of 26.9% from the April 30th total of 50,500 shares. Based on an average daily volume of 170,400 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the company's stock are sold short. View Spring Bank Pharmaceuticals' Current Options Chain.

Who are some of Spring Bank Pharmaceuticals' key competitors?

What other stocks do shareholders of Spring Bank Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), AMC Entertainment (AMC), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Apollo Global Management (APO), Chaarat Gold (CGH), SCYNEXIS (SCYX), China Unicom (Hong Kong) (CHU) and Ciena (CIEN).

Who are Spring Bank Pharmaceuticals' key executives?

Spring Bank Pharmaceuticals' management team includes the following people:
  • Mr. Martin J. Driscoll, Pres, CEO & Director (Age 60)
  • Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 69)
  • Dr. Nezam H. Afdhal, Chief Medical Officer (Age 62)
  • Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 41)
  • Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.

When did Spring Bank Pharmaceuticals IPO?

(SBPH) raised $14 million in an initial public offering on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

What is Spring Bank Pharmaceuticals' stock symbol?

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

Who are Spring Bank Pharmaceuticals' major shareholders?

Spring Bank Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Tiedemann Advisors LLC (2.14%), Parsons Capital Management Inc. RI (0.49%), Exane Derivatives (0.49%), JPMorgan Chase & Co. (0.29%), Bank of New York Mellon Corp (0.27%) and Acadian Asset Management LLC (0.20%). Company insiders that own Spring Bank Pharmaceuticals stock include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View institutional ownership trends for Spring Bank Pharmaceuticals.

Which institutional investors are selling Spring Bank Pharmaceuticals stock?

SBPH stock was sold by a variety of institutional investors in the last quarter, including Tiedemann Advisors LLC, and Parsons Capital Management Inc. RI. View insider buying and selling activity for Spring Bank Pharmaceuticals.

Which institutional investors are buying Spring Bank Pharmaceuticals stock?

SBPH stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives, JPMorgan Chase & Co., Bank of New York Mellon Corp, and Acadian Asset Management LLC. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include Jonathan Freve, Martin J Driscoll, and Scott Andrew Smith. View insider buying and selling activity for Spring Bank Pharmaceuticals.

How do I buy shares of Spring Bank Pharmaceuticals?

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spring Bank Pharmaceuticals' stock price today?

One share of SBPH stock can currently be purchased for approximately $1.65.

How big of a company is Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals has a market capitalization of $28.20 million. The company earns $-24,100,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.

What is Spring Bank Pharmaceuticals' official website?

The official website for Spring Bank Pharmaceuticals is www.springbankpharm.com.

How can I contact Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.